PAI-1 Inhibitors

Geodin is an isochromene derivative originally isolated from fungi. In the context of PAI-1 (Plasminogen Activator Inhibitor-1) inhibition, it targets the protein's active site or reactive center loop. By doing so, Geodin disrupts PAI-1's ability to inhibit target proteases like tissue plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). This results in the facilitation of plasminogen conversion to plasmin, a key enzyme in fibrinolysis, thus modulating the fibrinolytic system.

1,2,3,4,6-Penta-O-galloyl-β-D-glucopyranose is a polyphenolic compound commonly found in various plants. As a PAI-1 inhibitor, it targets the active site of PAI-1, obstructing its ability to bind to and inhibit target proteases such as tissue plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). This disruption facilitates the conversion of plasminogen to plasmin, an enzyme that plays a pivotal role in fibrinolysis. By inhibiting PAI-1, the compound acts as a modulator of the fibrinolytic system.

TGF-β RI Kinase Inhibitor VIII (CAS 356559-20-1) is a small-molecule inhibitor that targets the Transforming Growth Factor-beta Receptor I (TGF-β RI) kinase. By inhibiting this kinase, the compound indirectly reduces the expression and activation of PAI-1. Unlike direct PAI-1 inhibitors, it modulates the upstream signaling pathways that lead to PAI-1 expression. The inhibition of TGF-β RI kinase results in decreased PAI-1 levels, thereby affecting the overall balance of the fibrinolytic system.

Corilagin (CAS 23094-69-1) is a polyphenolic compound found in various plants. As a PAI-1 inhibitor, it targets the active site of PAI-1, disrupting its ability to inhibit proteases like tissue plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). This facilitates the conversion of plasminogen to plasmin, an enzyme crucial in fibrinolysis. Corilagin thus acts as a modulator of the fibrinolytic system.

Anacardic Acid inhibits PAI-1 by binding to its reactive center loop, thereby disrupting its interaction with target proteases like uPA and tPA, which leads to enhanced fibrinolytic activity.

TBB acts as a PAI-1 inhibitor by disrupting the active conformation of PAI-1, which prevents it from binding to its target proteases like tPA and uPA, leading to enhanced fibrinolysis.